Kancera reports that the company is initiating the development of a vaccine directed against ROR. This initiative is motivated by the residual disease in the form of a small number of cancer cells that remain in some patients despite...
Read MoreKancera announces the discovery of a new class of compounds that inhibits the epigenetic enzyme histone deacetylase 6 (HDAC6) and thereby controls the activity of the cancer cell genes. Severe side effects, due to poor selectivity, have limited the...
Read MoreKancera together with international research groups in the project A-PARADDISE has been awarded a grant from the European Union Seventh Framework Programme to develop drugs to combat severe parasitic diseases including malaria, schistosomiasis, leishmaniasis and Chagas disease. The total...
Read MoreKancera reports progress in the development of a ROR-inhibiting cancer drug. The compound KAN0439365 is effective against cancer cells from patients and show good metabolic stability in human liver cells and blood. KAN0439365 is the first in a new...
Read MoreKancera reports results from a collaboration with Professor Håkan Mellstedts research group at Karolinska Institute showing that the survival of an aggressive type of human cancer cells from pancreatic cancer is ROR-1 dependent. The results provide further support for...
Read MoreKancera reports that the company's first generation of PFKFB3 inhibiting compounds reduces growth of pancreatic cancer in a pre-clinical animal study.
Read MoreNEW YORK and STOCKHOLM, Oct. 04, 2012 - Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of proteinopathies, and iNovacia, a subsidiary to Kancera AB ...
Read MoreKancera announces that it has signed an agreement with Bioinvent to acquire BioInvent ́s rights to the patent application WO 2011/079902, covering therapeutic antibodies directed against the ROR receptor for treatment of cancer.
Read MoreKancera AB today announced that Dr. Thomas Olin, CEO of Kancera, will present the company at the 2012 BIO International Convention taking place June 18-21 in Boston, USA.
Read MoreKancera's inhibitors of ROR1 show an effect on leukemia cells from patients for whom standard therapy is not currently working. Kancera's partner and co-founder Professor Håkan Mellstedt and his research group at the Karolinska University Hospital conducted the studies.
Read More